Literature DB >> 15869596

Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.

T D Jones1, W J Phillips, B J Smith, C A Bamford, P D Nayee, T P Baglin, J S H Gaston, M P Baker.   

Abstract

BACKGROUND: The development of inhibitors in hemophiliacs is a severe complication of factor VIII (FVIII) replacement therapy and is a process driven by FVIII specific T helper cells.
OBJECTIVES: To finely map T cell epitopes within the whole FVIII protein in order to investigate the possibility of engineering FVIII variants with reduced propensity for inhibitor development. PATIENTS AND METHODS: T cell lines were generated from five patients with severe hemophilia who had developed inhibitors, and were screened for T cell proliferation against pools of overlapping peptides spanning the entire B domain deleted (BDD) FVIII sequence. Positive peptide pools were decoded by screening individual peptides against the T cell lines. Positive peptides, and mutants thereof, were tested for their ability to bind major histocompatibility complex (MHC) Class II and stimulate T cell proliferation in a panel of healthy donors. The activities of the corresponding mutant proteins were assessed via chromogenic assay.
RESULTS: One peptide, spanning FVIII amino acids 2098-2112, elicited a vigorous response from one hemophiliac donor, induced strong T cell responses in the panel of healthy donors and bound to a number of HLA-DR alleles. Mutations were made in this peptide that removed its ability to stimulate T cells of healthy donors and to bind to MHC Class II while retaining full activity when incorporated into a mutant BDD-FVIII protein.
CONCLUSIONS: Fine T cell epitope mapping of the entire FVIII protein is feasible, although challenging, and this knowledge may be used to create FVIII variants which potentially have reduced immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869596     DOI: 10.1111/j.1538-7836.2005.01309.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  38 in total

1.  HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

Authors:  R A Ettinger; E A James; W W Kwok; A R Thompson; K P Pratt
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

2.  von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.

Authors:  Nicoletta Sorvillo; Robin B Hartholt; Esther Bloem; Magdalena Sedek; Anja ten Brinke; Carmen van der Zwaan; Floris P van Alphen; Alexander B Meijer; Jan Voorberg
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

3.  Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions.

Authors:  Sandeep Kumar; Satish K Singh; Xiaoling Wang; Bonita Rup; Davinder Gill
Journal:  Pharm Res       Date:  2011-03-25       Impact factor: 4.200

4.  Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.

Authors:  Regina S Salvat; Deeptak Verma; Andrew S Parker; Jack R Kirsch; Seth A Brooks; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

5.  Structure-guided deimmunization of therapeutic proteins.

Authors:  Andrew S Parker; Yoonjoo Choi; Karl E Griswold; Chris Bailey-Kellogg
Journal:  J Comput Biol       Date:  2013-02       Impact factor: 1.479

Review 6.  Preclinical models used for immunogenicity prediction of therapeutic proteins.

Authors:  Vera Brinks; Daniel Weinbuch; Matthew Baker; Yann Dean; Philippe Stas; Stefan Kostense; Bonita Rup; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

7.  A high throughput MHC II binding assay for quantitative analysis of peptide epitopes.

Authors:  Regina Salvat; Leonard Moise; Chris Bailey-Kellogg; Karl E Griswold
Journal:  J Vis Exp       Date:  2014-03-25       Impact factor: 1.355

8.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

Review 9.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

10.  Optimization algorithms for functional deimmunization of therapeutic proteins.

Authors:  Andrew S Parker; Wei Zheng; Karl E Griswold; Chris Bailey-Kellogg
Journal:  BMC Bioinformatics       Date:  2010-04-09       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.